Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists

N Engl J Med. 2024 May 30;390(20):1839-1842. doi: 10.1056/NEJMp2400978. Epub 2024 Apr 17.

Authors

Ezekiel J Emanuel¹, Johan L Dellgren¹, Matthew S McCoy¹, Govind Persad¹

Affiliation

¹ From the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia (E.J.E., J.L.D., M.S.M.); the Bergen Center for Ethics and Priority Setting, University of Bergen, Bergen, Norway (E.J.E., J.L.D., M.S.M., G.P.); and the Sturm College of Law, University of Denver, Denver (G.P.).

PMID: 38630999
DOI: 10.1056/NEJMp2400978

No abstract available

MeSH terms

Anti-Obesity Agents / therapeutic use
Delivery of Health Care* / economics
Delivery of Health Care* / ethics
Delivery of Health Care* / ethnology
Delivery of Health Care* / standards
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Glucagon-Like Peptide 1 / agonists
Glucagon-Like Peptide-1 Receptor Agonists / supply & distribution
Glucagon-Like Peptide-1 Receptor Agonists / therapeutic use
Health Services Accessibility / economics
Healthcare Disparities / economics
Healthcare Disparities / ethnology
Humans
Hypoglycemic Agents* / therapeutic use
Obesity* / complications
Obesity* / drug therapy
Obesity* / epidemiology
Receptors, Gastrointestinal Hormone* / agonists
Risk
United States / epidemiology

Substances

gastric inhibitory polypeptide receptor
Glucagon-Like Peptide 1
Hypoglycemic Agents
Receptors, Gastrointestinal Hormone
Glucagon-Like Peptide-1 Receptor Agonists
Anti-Obesity Agents